The current PCT application will be widely extended into national phases in order to provide a strong territorial protection, which will be the foundation for future patents covering new chemical entities implementing the TfR VECTrans® technology.
Vect-Horus patents are jointly owned by Vect-Horus’ historical academic partners, the CNRS and Aix-Marseille University (AMU) as the result of a long term and fruitful collaboration with the Institute of NeuroPhysiopathology (INP-UMR7051) directed by Dr. Michel Khrestchatisky, co-founder of the company.